Compulsive overeating and binge eating disorder: mechanisms, risk factors, and evidence-based treatment strategies

Compulsive overeating and binge eating disorder (BED) are clinical conditions defined by maladaptive patterns of eating that produce distress or impairment. While occasional overeating is common, BED involves recurrent binge-eating episodes—eating, in a discrete period, an amount of food that is objectively large, accompanied by a perceived loss of control. The core medical issue is not simply high caloric intake but a dysregulated neurobehavioral system integrating reward processing, stress reactivity, inhibitory control, and cognitive appraisal.

BED is typically characterized by episodes occurring at least weekly for a duration of months, with additional features: eating rapidly, eating until uncomfortably full, eating large amounts when not physically hungry, eating alone due to embarrassment, and experiencing marked distress afterward. Many patients show comorbidities including major depressive disorder, anxiety disorders, substance-use disorders, post-traumatic stress disorder, and obesity. Bed is therefore best conceptualized as a biopsychosocial syndrome rather than a purely behavioral choice.

Mechanistically, BED is influenced by altered dopaminergic reward signaling, heightened salience of food cues, and impaired top-down regulation from prefrontal networks. Functional neuroimaging studies commonly show stronger cue-evoked activation in reward-related circuitry and reduced activation or efficiency in cognitive control regions. Stress can precipitate binges via hypothalamic-pituitary-adrenal (HPA) axis dysregulation, increasing vulnerability to negative reinforcement—eating to relieve dysphoria rather than to satisfy hunger.

Neurobiologically, insulin and gut-brain signaling pathways (including leptin, ghrelin, and incretin hormones) modulate satiety and hedonic eating. In BED, satiety signals may be less effective or weighted differently relative to reward cues. Sleep disruption, circadian misalignment, and inflammatory changes (e.g., elevated markers of low-grade inflammation reported in some populations) can further impair appetite regulation and mood, perpetuating a cycle of restriction, binge, shame, and renewed restriction.

Risk factors include female sex, younger age at onset, a history of weight cycling, chronic dieting, and early-life adversity (emotional, physical, or sexual trauma). Psychological drivers often include emotion regulation difficulties: individuals may use eating to manage anxiety, sadness, anger, loneliness, or stress. Cognitive processes such as rigid dietary rules and all-or-nothing thinking can convert normal hunger into an impending “permission” to binge. Impulsivity traits and reduced distress tolerance can amplify episodes when coping resources are overwhelmed.

Medical consequences are significant. BED is associated with obesity and related complications (type 2 diabetes, dyslipidemia, hypertension, nonalcoholic fatty liver disease, and obstructive sleep apnea). Even independent of body mass, BED correlates with gastrointestinal discomfort, reduced quality of life, functional impairment, and increased healthcare utilization. Importantly, binge eating may involve eating in secrecy, contributing to social withdrawal and worsening comorbid depression.

Evidence-based treatment integrates psychotherapy, nutritional/medical management, and—when indicated—pharmacotherapy. First-line psychotherapy includes cognitive-behavioral therapy for BED (CBT-BED), which targets the binge cycle by normalizing eating patterns, addressing triggers, improving cognitive flexibility, and developing alternative coping strategies. Interpersonal therapy (IPT) focuses on role transitions, interpersonal conflicts, and grief-related processes that can trigger dysregulated eating.

Pharmacologic options may be considered for moderate to severe BED, particularly when psychotherapy alone is insufficient. Lisdexamfetamine has demonstrated benefit in reducing binge-eating frequency in appropriate patients. Selective serotonin reuptake inhibitors (SSRIs) and other agents may help with comorbid depression or anxiety and can reduce binge frequency in some cases. For patients with obesity or insulin resistance, careful metabolic management is essential, though weight-loss interventions must be implemented cautiously to avoid triggering restriction-driven binges. Emerging approaches include GLP-1 receptor agonists, which can improve appetite and satiety, but individual risk-benefit assessment remains necessary.

A critical medical objective is differentiating BED from other binge-related disorders: bulimia nervosa (recurrent compensatory behaviors), binge-eating episodes due to medical conditions or medications (e.g., corticosteroid effects), and simple overeating without loss of control. Clinicians also screen for eating disorder history, suicidal ideation, and comorbid substance use. Assessment typically includes structured interviews (such as DSM-5-TR criteria), symptom frequency tracking, and evaluation of physical health parameters.

Prognosis varies, but timely, structured care improves outcomes. Many patients experience symptom reduction with sustained therapy, especially when coping skills and self-monitoring are developed and when comorbid depression or anxiety is treated. Relapse prevention is a standard component: triggers such as stress, social isolation, sleep loss, and dietary restraint are addressed through behavioral plans and contingency strategies.

If a person recognizes a recurring pattern of binge eating with loss of control and distress, prompt evaluation by a clinician is warranted. Early intervention can reduce medical risk, restore adaptive eating behaviors, and improve psychological well-being.

Source: DesertBellyCub (X/Twitter).